Filtered By:
Infectious Disease: Hepatitis B
Therapy: Chemotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 267 results found since Jan 2013.
Exam 2: Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy
Source: Clinical Gastroenterology and Hepatology - March 15, 2015 Category: Gastroenterology Tags: Continuing Medical Education (CME) Activities Source Type: research
The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours
Conclusion
High levels of anti-HBs may have a protective effect against the reactivation of HBV especially in patients with haematological malignancies who received immunosuppressive anticancer therapy.
Source: Journal of International Medical Research - May 24, 2016 Category: Research Authors: Yilmaz, B., Erdem, D., Teker, F., Goren, I., Yildirim, B., Kut, E., Sarikaya, D., Atay, M. H., Yucel, I. Tags: Clinical Reports Source Type: research
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
ConclusionIdentification of anti-HBs-negative subgroups is critical to improve the cost-effectiveness of prophylactic antiviral therapy in lymphoma patients with resolved HBV infection.
Source: Journal of the Formosan Medical Association - June 22, 2019 Category: General Medicine Source Type: research
Oncogenic β-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesis
CONCLUSION: MTX is a promising chemotherapeutic agent for β-catenin hyperactive liver cancer. Since repurposing MTX has the advantages of lower risk, shorter timelines, and less investment in drug discovery and development, a clinical trial is warranted to test its efficacy in the treatment of β-catenin mutant liver cancer.PMID:37612257 | DOI:10.1097/CM9.0000000000002816
Source: Chinese Medical Journal - August 23, 2023 Category: General Medicine Authors: Fangming Liu Yuting Wu Baohui Zhang Shuhui Yang Kezhuo Shang Jie Li Pengju Zhang Weiwei Deng Linlin Chen Liang Zheng Xiaochen Gai Hongbing Zhang Source Type: research
The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis
Conclusion Lamivudine prophylaxis in HBsAg seropositive breast cancer patients undergoing chemotherapy is effective in reducing HBV reactivation and HBV-associated morbidity and mortality.
Source: Journal of the Formosan Medical Association - February 10, 2015 Category: Journals (General) Source Type: research
Prevalence of occult hepatitis B infection in patients visiting tertiary care hospital
Conclusion HBV DNA amplification may under diagnose OBI and anti-HBc total positivity may be a better surrogate marker. Nucleic acid testing of blood donors, however is preferred, especially in high endemic areas. OBI must be looked for in cirrhotics, HIV infection, and patients with cancers prior to chemotherapy, as they may contribute to morbidity in them.
Source: Medical Journal Armed Forces India - April 18, 2016 Category: Journals (General) Source Type: research
Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
Conclusion Clinical outcomes were not different between LVD and ETV users. Delayed detection of hepatitis flare-up with coagulopathy and a high viral load could result in a poor prognosis.
Source: Journal of the Chinese Medical Association - September 30, 2017 Category: General Medicine Source Type: research
Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study
Journal of Medical Virology,Volume 0, Issue ja, -Not available-.
Source: Journal of Medical Virology - June 14, 2018 Category: Virology Authors: Hwi YoungKim
,
Jeong ‐JuYoo
,
SoheeOh
,
Su JongYu
,
Yoon JunKim
,
Jung‐HwanYoon
,
WonKim
,
Yong JinJung
,
Bo HyunKim
,
Chang‐MinKim
,
Joong‐WonPark
,
Jeong‐HoonLee Source Type: research
Taiwan consensus statement on the management of chronic hepatitis B
Publication date: Available online 6 December 2018Source: Journal of the Formosan Medical AssociationAuthor(s): Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Tsung-Hui Hu, Hwa-I Yang, Sheng-Nan Lu, Yen-Hsuan Ni, Won-Long Chuang, Chuan-Mo Lee, Jaw-Chin Wu, Pei-Jer Chen, Yun-Fan LiawThe experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the sta...
Source: Journal of the Formosan Medical Association - December 6, 2018 Category: General Medicine Source Type: research
Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland - a report of the Polish Lymphoma Research Group.
Conclusions: In Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient. We should intensify educational strategies in the global oncohematologic medical community.
PMID: 32051719 [PubMed]
Source: Archives of Medical Science - February 15, 2020 Category: General Medicine Tags: Arch Med Sci Source Type: research
Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
Conclusion Continuing of the operation of an automatic check system using coded medical information to check for the reactivation enabled this prospective study of HBV reactivation. Careful attention should be paid to patients using steroids, as well as malignant lymphoma patients who are treated with rituximab. The results of the present study suggest that the present IT encoding system would be useful for preventing HBV reactivation.
PMID: 33055468 [PubMed - in process]
Source: Internal Medicine - October 20, 2020 Category: Internal Medicine Tags: Intern Med Source Type: research
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news
